Clinical Trial Update: CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers [Phase 3]

View source ↗

Summary

This report notes the completion of a Phase 3b safety study evaluating catumaxomab, administered intraperitoneally, for malignant ascites caused by epithelial c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Carcinoma
• Malignant Ascites
• Neoplasm

Drugs mentioned

• Catumaxomab (Catumaxomab)

Snippet

Sponsor: Neovii Biotech | Conditions: Cancer, Neoplasms | Phase 3 | Status: COMPLETED